<DOC>
	<DOCNO>NCT00813241</DOCNO>
	<brief_summary>A pharmacokinetic study healthy volunteer determine relative bioavailability three formulation celecoxib approve formulation .</brief_summary>
	<brief_title>A Pilot Open-Label Crossover Bioavailability Study Celecoxib Healthy Volunteers</brief_title>
	<detailed_description>Pharmacokinetics</detailed_description>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Healthy male and/or female subject age 21 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure ( BP ) pulse rate measurement , 12lead ECG clinical laboratory test ) ; Body Mass Index ( BMI ) approximately 18 32 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . A BMI low limit 17.5kg/m2 may round 18.0 kg/m2 , BMI upper limit 32.5 kg/m2 may round 32.0 kg/m2 acceptable inclusion ; Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect trial ; Subjects willing able comply schedule visit , treatment plan , laboratory test , trial procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) ; Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen ; History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) , within 6 month screen ; Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day ; Treatment investigational drug within 30 day 5 halflives precede first dose study medication ; 12lead ECG demonstrate QTc &gt; 450 msec Screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility ; Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception , outline protocol , least 14 day prior first dose study medication completion followup procedure ; Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement hormonal method contraception ( include oral transdermal contraceptive , injectable progesterone , progestin subdermal implant , progesteronereleasing IUDs , postcoital contraceptive method ) hormone replacement therapy must discontinue 28 day prior first dose study medication . DepoProveraÂ® must discontinue least 6 month prior first dose study medication . As exception , acetaminophen/paracetamol may use dos less equal 1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor ; Use grapefruit containing product within least 7 day prior administration study medication ; Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose ; History sensitivity heparin heparininduced thrombocytopenia ; Unwilling unable comply Lifestyle guideline describe protocol ; Subjects preexist asthma , know hypersensitivity celecoxib , experience asthma , urticaria allergictype reaction take sulfonamide , aspirin , selective COX2 inhibitor , nonsteroidal antiinflammatory drug ( NSAIDs ) ; Subjects prior history ulcer disease gastrointestinal bleeding ; Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Ankylosing spondylitis , Rheumatoid Arthritis , Adenomatous Polyposis Coli , Osteoarthritis , Dysmenorrhoea , pharmacokinetic study</keyword>
</DOC>